Nexalin Technology, Inc.
NXL · XNASCIK 1527352fmd_0YK1GG9X26BAKY8DBKEW2H9MJQManufacturing · Electromedical & Electrotherapeutic ApparatusTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 24 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | – | 0 | 1 | 0 | 0 | 0 |
| Cost of revenue | – | 0 | 0 | 0 | 0 | 0 |
| Net interest income | – | – | – | 0 | (0) | (0) |
| Gross profit | – | 0 | 1 | 0 | 0 | 0 |
| Research and development | 2 | 0 | 1 | 2 | 1 | 1 |
| Selling, general and administrative | – | 5 | 1 | 2 | 4 | 4 |
| Compensation and benefits | – | 0 | 1 | 1 | 2 | 2 |
| Total operating expenses | – | 6 | 3 | 6 | 8 | 9 |
| Operating income | – | (6) | (2) | (6) | (8) | (8) |
| Interest expense | – | 0 | 0 | 0 | (0) | (0) |
| Other non-operating income (expense) | – | (0) | 0 | 1 | 0 | 0 |
| Income before taxes | – | – | – | (5) | (8) | (8) |
| Net income | – | (6) | (2) | (5) | (8) | (8) |